A Phase II Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure - AZD0780-ABPM

Study identifier:D7960C00009

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A Phase II Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants with Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-Density Lipoprotein Cholesterol.

Medical condition

Atherosclerotic Cardiovascular Disease

Phase

Phase 2

Healthy volunteers

No

Study drug

Placebo, AZD0780

Sex

All

Estimated Enrollment

172

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 28 Oct 2024
Estimated Primary Completion Date: 31 Mar 2025
Estimated Study Completion Date: 31 Mar 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Crossover Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Fortrea

Inclusion and exclusion criteria